KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Change in Accured Expenses (2025 - 2026)

Teva Pharmaceutical Industries filings provide 2 years of Change in Accured Expenses readings, the most recent being -$144.0 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 251.22% to -$144.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $218.4 million, a 70.62% decrease, with the full-year FY2025 number at -$15.0 million, down 105.81% from a year prior.
  • Change in Accured Expenses hit -$144.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from -$41.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of -$41.0 million in Q1 2025 to a low of -$144.0 million in Q1 2026.